Sun Pharmaceuticals Industries Ltd on Thursday, April 10 said the US Court of Appeals for the Federal Circuit has ruled in favour of the company and vacated its preliminary injunction of delaying the launch of Leqselvi (deuruxolitinib), effective immediately.

The medication is intended for treating severe alopecia areata.

The US Court of Appeals for the Federal Circuit had held an oral argument on the company’s appeal of the US District Court’s decision that had previously granted the injunction in November 2024

delaying the said launch in the country.

However, the litigation between Incyte Corporation and the company continues.

Sun Pharma said it will disclose its launch plans in due course of time.

The US District Court’s injunction came after Sun Pharma had filed a challenge against it on August 1, 2024.

However, the court upheld the delay in November 2024, effectively halting the drug’s release in the US market. In response, Sun Pharma stated its disagreement with the ruling and plans to appeal.

Sun Pharma shares ended the Wednesday’s trade session 2.17% lower at ₹1,651.75 apiece. The stock has declined 12.6% this year, so far.